153 related articles for article (PubMed ID: 28481142)
21. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
22. [In vitro activity of daptomycin against VRE and MRSA strains].
Aktaş G; Derbentli S
Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722
[TBL] [Abstract][Full Text] [Related]
23. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation.
Wei XC; Zhao MF; Li X; Xiao X
J Clin Pharmacol; 2020 Jun; 60(6):768-774. PubMed ID: 32080861
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
[TBL] [Abstract][Full Text] [Related]
26. β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus.
Berti AD; Sakoulas G; Nizet V; Tewhey R; Rose WE
Antimicrob Agents Chemother; 2013 Oct; 57(10):5005-12. PubMed ID: 23896478
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.
Hindler JA; Wong-Beringer A; Charlton CL; Miller SA; Kelesidis T; Carvalho M; Sakoulas G; Nonejuie P; Pogliano J; Nizet V; Humphries R
Antimicrob Agents Chemother; 2015 Jul; 59(7):4279-88. PubMed ID: 25963982
[TBL] [Abstract][Full Text] [Related]
28. False daptomycin-nonsusceptible MIC results by Microscan panel PC 29 relative to Etest results for Staphylococcus aureus and enterococci.
Palavecino EL; Burnell JM
J Clin Microbiol; 2013 Jan; 51(1):281-3. PubMed ID: 23077121
[TBL] [Abstract][Full Text] [Related]
29. In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus.
Chang Y; Chen WC; Hsieh PH; Chen DW; Lee MS; Shih HN; Ueng SW
Antimicrob Agents Chemother; 2011 Dec; 55(12):5480-4. PubMed ID: 21930872
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
31. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.
Smith JR; Barber KE; Raut A; Aboutaleb M; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2015; 70(6):1738-43. PubMed ID: 25645208
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of daptomycin and comparator agents against Staphylococcus aureus isolates from intravenous drug users with right endocarditis.
Sanchez-Porto A; Casanova-Roman M; Casas-Ciria J; Santaella MJ; Sanchez-Morenilla I; Eiros-Bouza JM
Infez Med; 2010 Jun; 18(2):108-12. PubMed ID: 20610933
[TBL] [Abstract][Full Text] [Related]
34. Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs.
Diaz L; Tran TT; Munita JM; Miller WR; Rincon S; Carvajal LP; Wollam A; Reyes J; Panesso D; Rojas NL; Shamoo Y; Murray BE; Weinstock GM; Arias CA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4527-34. PubMed ID: 24867964
[TBL] [Abstract][Full Text] [Related]
35. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding.
Dhand A; Bayer AS; Pogliano J; Yang SJ; Bolaris M; Nizet V; Wang G; Sakoulas G
Clin Infect Dis; 2011 Jul; 53(2):158-63. PubMed ID: 21690622
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of benzenesulfonanilides active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
Namba K; Zheng X; Motoshima K; Kobayashi H; Tai A; Takahashi E; Sasaki K; Okamoto K; Kakuta H
Bioorg Med Chem; 2008 Jun; 16(11):6131-44. PubMed ID: 18468909
[TBL] [Abstract][Full Text] [Related]
37. Glycopeptide and daptomycin susceptibility and vancomycin heteroresistance of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates from a Greek university hospital.
Panagea T; Galani I; Souli M; Karantani I; Giamarellou H; Petrikkos G
Int J Antimicrob Agents; 2011 Nov; 38(5):451-2. PubMed ID: 21840688
[No Abstract] [Full Text] [Related]
38. Bacterial susceptibility in bloodstream infections: Results from China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2015-2016.
Zhang F; Li Y; Lv Y; Zheng B; Xue F
J Glob Antimicrob Resist; 2019 Jun; 17():276-282. PubMed ID: 30611932
[TBL] [Abstract][Full Text] [Related]
39. A current perspective on daptomycin for the clinical microbiologist.
Humphries RM; Pollett S; Sakoulas G
Clin Microbiol Rev; 2013 Oct; 26(4):759-80. PubMed ID: 24092854
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
Belley A; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
